In summary, our results demonstrate that AAV-mediated delivery of CasRx can potently knock down Vegfa mRNA and suppress pathogenic CNV development in a mouse model of AMD, supporting the notion that the RNA-targeting CRISPR system could be useful for therapeutic purposes. The gene discussed is VEGFA; the disease is age-related macular degeneration.